Elucidating the neuropathological and molecular heterogeneity of amyloid beta and tau in Alzheimer's disease through machine learning and transcriptomic integration
Alzheimer's & Dementia · 2026
DOI: 10.1002/alz.71757 ↗Kurz gefasst
Fachartikel in der Zeitschrift Alzheimer's & Dementia, 2026. Verfasst von Kanhao Zhao und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Bioengineering, Lehigh University, Bethlehem, Pennsylvania, USA. Hauptthemen laut MEDLINE: Alzheimer Disease, tau Proteins, Amyloid beta-Peptides, Machine Learning. Die Arbeit nennt 135 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NIA NIH HHS, Alzheimer's Association, Stanford Knight Initiative for Brain Resilience and the Rosenkranz Foundation grant.
Abstract (Originalsprache)
INTRODUCTION Functional brain network alterations associated with Alzheimer's disease (AD) pathology, including amyloid beta (Aβ) and phosphorylated tau (p‐tau), are difficult to interpret due to overlapping aging‐associated and non‐amyloid biological processes. METHODS We analyzed resting‐state functional magnetic resonance imaging (fMRI) from 289 older adults classified as Aβ‐positive (A + , n = 129) or Aβ‐negative (A − , n = 160) based on cerebrospinal fluid biomarkers. A contrastive deep learning framework was used to identify A + ‐specific network dimensions and predict individual Aβ and p‐tau levels. RESULTS A + ‐specific signatures were localized to the right superior temporal and anterior cingulate cortices and linked to attention and memory functions, with transcriptomic enrichment implicating synaptic dysfunction and glial activity. In contrast, signature dimensions shared between A + and A − individuals involved language‐related regions and aging‐associated molecular pathways. CONCLUSION These findings suggest that contrastive graph learning may help separate amyloid‐associated functional network variation from broader background biological variability, providing insight into the heterogeneity of AD‐related biomarkers and cognitive dysfunction.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Bioengineering, Lehigh University, Bethlehem, Pennsylvania, USA.
- Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Stanford, California, USA.
- Center for Neuroscience Research, Children's National Hospital, Washington, District of Columbia, USA.
- George Washington University School of Medicine, Washington, District of Columbia, USA.
- Penn State College of Medicine, Hershey, Pennsylvania, USA.
- Department of Psychiatry, New York University Grossman School of Medicine, New York, New York, USA.
ORCID-Profile: Kanhao Zhao, Yu Zhang
Förderung
- NIA NIH HHS
- Alzheimer's Association
- Stanford Knight Initiative for Brain Resilience and the Rosenkranz Foundation grant
- NHLBI NIH HHS
- National Institute on Aging
Zitieren
APA
Zhao, K., Xie, H., Jacobs, T., Gaggi, N. L., Fortea, J., Carlisle, N. B., Fonzo, G. A., Pohl, K. M., Osorio, R. S., Zhang, Y., & ADNI Study Group and the PREVENT‐AD Research Group (2026). Elucidating the neuropathological and molecular heterogeneity of amyloid beta and tau in Alzheimer's disease through machine learning and transcriptomic integration. Alzheimer's & Dementia. https://doi.org/10.1002/alz.71757
Vancouver
Zhao K, Xie H, Jacobs T, Gaggi NL, Fortea J, Carlisle NB, et al. Elucidating the neuropathological and molecular heterogeneity of amyloid beta and tau in Alzheimer's disease through machine learning and transcriptomic integration. Alzheimer's & Dementia. 2026. doi:10.1002/alz.71757
BibTeX
@article{Zhao2026,
author = {Zhao, Kanhao and Xie, Hua and Jacobs, Tovia and Gaggi, Naomi L and Fortea, Juan and Carlisle, Nancy B and Fonzo, Gregory A and Pohl, Kilian M and Osorio, Ricardo S and Zhang, Yu and ADNI Study Group and the PREVENT‐AD Research Group, ADNI Study Group and the PREVENT‐AD Research Group},
title = {Elucidating the neuropathological and molecular heterogeneity of amyloid beta and tau in Alzheimer's disease through machine learning and transcriptomic integration},
journal = {Alzheimer's & Dementia},
year = {2026},
doi = {10.1002/alz.71757}
}
EUVIMED